Acute Decompensated Heart Failure Clinical Trial
Official title:
Clinical Observational Study of Remote, Non-invasive, Multidomain Endpoints in Patients Recovering From Acute Decompensated Heart Failure
NCT number | NCT06243029 |
Other study ID # | D1840M00072 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 8, 2024 |
Est. completion date | May 14, 2025 |
This study aims to evaluate the utility of a wearable heart monitoring patch that can be worn on the body to collect various measurements related to heart failure and develop a concept to potentially be used as a new measurement. It is crucial to test out new ways that make it easier to do research for new drugs and increase our chances of knowing how well they will work early on in the development process. Results from this study will be useful in planning future development programs for drugs aimed at treating patients with heart disease. This study will be conducted in a single hospital, it is non-randomised (not chosen by chance), exploratory, study in the United Kingdom (University Hospitals of Leicester NHS Trust). It aims to involve up to 80 men and women recently admitted due to sudden, severe heart failure symptoms. Participants will be part of the study for about two months, with one hospital visit after discharge, as commonly done in heart failure centres. - Visit 1 (Pre-Screening/Screening/Enrolment) will assess the participant's eligibility for participating in the study and for collecting data following hospitalisation for acute decompensated heart failure (ADHF). Participants will be trained and receive an ECG patch to wear from that moment onwards at home for a period of 4 to 7 days. - Visit 2 (Follow-up visit) will be conducted approximately 6-8 weeks post Visit 1 and this will be the final study-related site visit. Participants will receive an ECG patch to wear at home for a second time for a period of 4 to 7 days. - Visit 3 (Review of Medical Records). It is a review of the health status using medical records by the study team. The participant is not expected to attend the hospital for any appointments
Status | Recruiting |
Enrollment | 80 |
Est. completion date | May 14, 2025 |
Est. primary completion date | May 14, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Men and women aged 18 years or older - Confirmed diagnosis of heart failure according to the latest ESC criteria - Primary cause of hospitalisation due to decompensated heart failure - Willing and able to complete all visits and assessments as per protocol - Provision of signed and dated, written informed consent before any study-specific procedures. Exclusion Criteria: - Receiving renal replacement therapy - Implanted cardiac (or other) device in-situ, cardiac pacemaker, defibrillator, or other implanted electronic devices or other ventricular assist device in situ - Currently receiving chemotherapy - Receiving end-of-life care - Active severe infection: individuals with an active severe infection, as determined by the PI's clinical judgment, will not be eligible for study participation - Hypersensitivity to patch adhesive/ materials in the patch - Skin condition or damage that prevents wearing of the patch. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Research Site | Leicester |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in patch-measured variables between baseline and follow-up at 6-8 weeks (multiple variables) using the ECG patch. | 6-8 weeks | ||
Secondary | Data completeness overall and per ECG patch variable, participant adherence, signal to noise ratio, day versus night assessment of quality using the ECG patch. | 6-8 weeks | ||
Secondary | Correlation between a change in ECG patch variables (multiple) and change in KCCQ at 6-8 weeks after discharge from hospital following admission for ADHF. | 6-8 weeks | ||
Secondary | Correlation between clinical parameters e.g. NT-pro BNP, KCCQ, BP, HR and the patch variables using data from Visit 1 (multiple comparisons). | 6-8 weeks | ||
Secondary | Correlation between change in NT-proBNP, BP, HR, body weight, peripheral oedema extent, NYHA class etc. and change in the patch variables (multiple comparisons). | 6-8 weeks | ||
Secondary | Correlation between change in one minute sit to stand test, frailty score, hand grip test and the change in patch variables (multiple comparisons). | 6-8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04049045 -
Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure
|
Phase 2 | |
Active, not recruiting |
NCT05100836 -
SURPASS Impella 5.5 Study
|
||
Recruiting |
NCT02898181 -
Low Level Tragus Stimulation in Acute Decompensated Heart Failure
|
N/A | |
Completed |
NCT02823626 -
High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure
|
||
Completed |
NCT02196038 -
A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients
|
N/A | |
Completed |
NCT02248831 -
Evaluation of Cardiopulmonary Diseases by Ultrasound
|
N/A | |
Completed |
NCT00693745 -
Neutrophil Gelatinase-Associated Lipcalin (NGAL) Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF
|
N/A | |
Not yet recruiting |
NCT04391231 -
HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial
|
Phase 4 | |
Recruiting |
NCT05206422 -
DORAYA-HF Early Feasibility Study
|
N/A | |
Recruiting |
NCT01960218 -
Gas Exchange for Predicting Hospital Heart Failure Readmissions
|
N/A | |
Terminated |
NCT00904488 -
Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure
|
Phase 4 | |
Terminated |
NCT02620384 -
Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.
|
Phase 3 | |
Completed |
NCT04318093 -
Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure
|
Phase 2 | |
Recruiting |
NCT06161649 -
Mobile Education System to Improve Disease Knowledge, Self-efficacy and Quality of Life in Patients With Heart Failure
|
N/A | |
Completed |
NCT02289508 -
Role of USCOM in Adult Patients With Heart Failure
|
N/A | |
Terminated |
NCT01457053 -
Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics
|
N/A | |
Completed |
NCT04877652 -
DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics
|
||
Completed |
NCT03505788 -
Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR)
|
Phase 4 | |
Completed |
NCT03146754 -
A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes (LUPE)
|
N/A | |
Not yet recruiting |
NCT06414759 -
Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload
|
Phase 4 |